Alison Donnelly Axtman

This paper develops NanoBRET assays for PAK1 and its mutant in primary neurons to evaluate inhibitor target engagement.

This study develops and characterizes a potent and cell-active inhibitor of TTBK1 and TTBK2, with selectivity and potential therapeutic applications for neurodegenerative diseases.

The paper compares cell-free and cellular assays for kinase inhibitor selectivity, finding divergent results and identifying new kinase interactions in cells.

The paper develops a chemical probe, SGC-CK1γ-1, for the CK1γ subfamily, showing potent and selective inhibition of CK1γ kinases, WNT signaling, and HCMV replication.

The paper develops a NanoBRET assay to study SYK gain-of-function variants in live cells and demonstrates inhibitor efficacy against these variants.

The paper identifies and characterizes a chemical probe for CDKL2, demonstrating its selectivity and biological impact in neurons and cancer cells.

The paper identifies and optimizes narrow-spectrum TLK2 inhibitors using QSAR analysis and structural studies.

The paper synthesizes pyrimidoquinoline derivatives as CSNK2A inhibitors with antiviral activity, finding that certain substituents improve potency while maintaining solubility.

The paper identifies two covalent inhibitors that disrupt the interaction between SYK's tandem SH2 domains and FCER1G phospho-ITAM, potentially beneficial for Alzheimer's disease therapy.

This study identifies MSN and CD44 as potential therapeutic targets for Alzheimer's disease by developing inhibitors of their interaction through structural and chemical screening.

The paper develops specific CDKL5 inhibitors that do not affect GSK3β activity and shows their effects on synaptic function and LTP in rat hippocampal slices.

The paper compiles an annotated set of 171 small molecule modulators targeting 98 novel AD therapeutic proteins, serving as chemical tools for hypothesis validation.

The paper discusses the potential of kinase inhibitors for neurodegenerative diseases, highlighting the need for validated targets and strategies for drug discovery.